93,372 Shares in Cognition Therapeutics, Inc. (NASDAQ:CGTX) Acquired by Twin Focus Capital Partners LLC

Twin Focus Capital Partners LLC acquired a new stake in shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 93,372 shares of the company’s stock, valued at approximately $173,000.

Separately, Sigma Planning Corp purchased a new stake in Cognition Therapeutics in the 4th quarter worth about $53,000. 43.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on CGTX shares. HC Wainwright initiated coverage on shares of Cognition Therapeutics in a report on Wednesday, May 29th. They set a “buy” rating and a $10.00 price objective on the stock. Chardan Capital started coverage on shares of Cognition Therapeutics in a report on Thursday, June 6th. They issued a “buy” rating and a $11.00 price objective for the company. B. Riley restated a “buy” rating and set a $5.00 target price on shares of Cognition Therapeutics in a research report on Thursday, March 28th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $9.00 price target on shares of Cognition Therapeutics in a research report on Wednesday, March 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cognition Therapeutics presently has a consensus rating of “Buy” and an average price target of $8.20.

Cognition Therapeutics Stock Performance

Cognition Therapeutics stock traded down $0.03 during midday trading on Friday, hitting $2.17. 89,470 shares of the company’s stock were exchanged, compared to its average volume of 191,732. The stock has a 50-day moving average price of $2.03 and a two-hundred day moving average price of $1.99. The company has a market cap of $86.93 million, a P/E ratio of -2.36 and a beta of 1.53. Cognition Therapeutics, Inc. has a 52-week low of $0.90 and a 52-week high of $3.49.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Tuesday, May 7th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, sell-side analysts expect that Cognition Therapeutics, Inc. will post -0.97 earnings per share for the current year.

Cognition Therapeutics Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.